Bio Green Med Solution Inc (BGMS) Stock AnalysisBGMSStock AnalysisBio Green Med Solution Inc

Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., is a diversified company engaged in both the fire protection and biopharmaceutical industries. It develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. It provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel. It operates in the Healthcare sector.

Bio Green Med Solution Inc (BGMS) is not a good buy right now. The stock has a current price of $0.86, which is significantly down 39.01% year-to-date and 86.49% over the past year. The RSI is at 31.619, indicating it is oversold, but this could also suggest continued weakness. The forward P/E ratio is 0, reflecting uncertainty in future earnings, and the gross margin is only 23.51%, which is low for a biotech company. The main risk is the high net income loss of $425,000 in Q2 2026, which raises concerns about the company's financial health.